Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.46 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | HPGD | P15428 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | GLA | P06280 | 2/20 | 0.34 |
| ▸ | CASP1 | P29466 | 2/20 | 0.34 |
| ▸ | CASP7 | P55210 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31694955 | 1.00 | ELANE (0.46) | ELANENUDT1MAPTLMNACYP1A2 | |
| SCHEMBL31694921 | 0.82 | ELANE (0.49) | ELANENUDT1MAPTLMNACYP1A2 | |
| SCHEMBL18548985 | 0.82 | ELANE (0.49) | ELANENUDT1MAPTLMNACYP1A2 | |
| SCHEMBL31694934 | 0.79 | ELANE (0.46) | ELANENUDT1MAPTLMNACYP1A2 | |
| SCHEMBL18548984 | 0.79 | ELANE (0.46) | ELANENUDT1MAPTLMNACYP1A2 | |
| SCHEMBL31694957 | 0.79 | ELANE (0.46) | ELANENUDT1MAPTLMNACYP1A2 | |
| SCHEMBL31694932 | 0.79 | ELANE (0.46) | ELANENUDT1MAPTLMNACYP1A2 | |
| SCHEMBL17205186 | 0.79 | NUDT1 (0.54) | ELANENUDT1MAPTLMNACYP1A2 | |
| SCHEMBL18548994 | 0.79 | ELANE (0.46) | ELANENUDT1MAPTLMNACYP1A2 | |
| SCHEMBL18549020 | 0.79 | ELANE (0.46) | ELANENUDT1MAPTLMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12629356-B2 | Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2026-05-19 | — | — | US | claimed |
| EP-3565586-B1 | EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES WITH POTASSIUM CHANNEL AGONISTS AND THERAPEUTIC USES THEREOF | IOVANCE BIOTHERAPEUTICS INC (US) | 2025-10-08 | — | — | EP | claimed |
| US-20230210966-A1 | EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES WITH POTASSIUM CHANNEL AGONISTS AND THERAPEUTIC USES THEREOF | LION BIOTECHNOLOGIES, INC. | 2023-07-06 | — | — | US | claimed |
| US-11357841-B2 | Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2022-06-14 | — | — | US | claimed |
| EP-3565586-A1 | EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES WITH POTASSIUM CHANNEL AGONISTS AND THERAPEUTIC USES THEREOF | Iovance Biotherapeutics, Inc. (US) | 2019-11-13 | — | — | EP | claimed |
| WO-2018129336-A1 | EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES WITH POTASSIUM CHANNEL AGONISTS AND THERAPEUTIC USES THEREOF | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2018-07-12 | — | — | WO | claimed |
| US-20170056376-A1 | SELECTIVE ACTIVATORS OF THE INTERMEDIATE CONDUCTANCE CA2+ACTIVATED K+ CHANNEL KCa3.1 AND THEIR METHODS OF USE | UNIV CALIFORNIA (US) | 2017-03-02 | — | — | US | claimed |
| US-12629356-B2 | Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| EP-3565586-B1 | EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES WITH POTASSIUM CHANNEL AGONISTS AND THERAPEUTIC USES THEREOF | IOVANCE BIOTHERAPEUTICS INC (US) | 2025-10-08 | — | — | EP | disclosed |
| US-20230210966-A1 | EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES WITH POTASSIUM CHANNEL AGONISTS AND THERAPEUTIC USES THEREOF | LION BIOTECHNOLOGIES, INC. | 2023-07-06 | — | — | US | disclosed |
| US-11357841-B2 | Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2022-06-14 | — | — | US | disclosed |
| US-11173146-B2 | Selective activators of the intermediate conductance CA2+activated K+ channel KCa3.1 and their methods of use | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-11-16 | — | — | US | disclosed |
| US-11173146-B2 | Selective activators of the intermediate conductance CA2+activated K+ channel KCa3.1 and their methods of use | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-11-16 | — | — | US | disclosed |
| EP-3565586-A1 | EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES WITH POTASSIUM CHANNEL AGONISTS AND THERAPEUTIC USES THEREOF | Iovance Biotherapeutics, Inc. (US) | 2019-11-13 | — | — | EP | disclosed |
| WO-2018129336-A1 | EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES WITH POTASSIUM CHANNEL AGONISTS AND THERAPEUTIC USES THEREOF | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2018-07-12 | — | — | WO | disclosed |
| US-20170056376-A1 | SELECTIVE ACTIVATORS OF THE INTERMEDIATE CONDUCTANCE CA2+ACTIVATED K+ CHANNEL KCa3.1 AND THEIR METHODS OF USE | UNIV CALIFORNIA (US) | 2017-03-02 | — | — | US | disclosed |
| US-20170056376-A1 | SELECTIVE ACTIVATORS OF THE INTERMEDIATE CONDUCTANCE CA2+ACTIVATED K+ CHANNEL KCa3.1 AND THEIR METHODS OF USE | UNIV CALIFORNIA (US) | 2017-03-02 | — | — | US | disclosed |
| US-20170056376-A1 | SELECTIVE ACTIVATORS OF THE INTERMEDIATE CONDUCTANCE CA2+ACTIVATED K+ CHANNEL KCa3.1 AND THEIR METHODS OF USE | UNIV CALIFORNIA (US) | 2017-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11173146-B2 | Selective activators of the intermediate conductance CA2+activated K+ channel KCa3.1 and their methods of use | KCNN3, KCNN1, KCNN2 | ELANE 2595/4885NUDT1 2147/4885MAPT 4633/4885 |
| US-20230210966-A1 | EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES WITH POTASSIUM CHANNEL AGONISTS AND THERAPEUTIC USES THEREOF | KCNN3, KCNK3, KCNA3 | ELANE 2747/4885NUDT1 2617/4885MAPT 4868/4885 |
| US-12629356-B2 | Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof | PBK, IL2, KCNN3 | ELANE 4828/4885NUDT1 2879/4885MAPT 2417/4885 |
| US-11357841-B2 | Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof | KCNN3, KCNK3, KCNA3 | ELANE 2747/4885NUDT1 2617/4885MAPT 4868/4885 |
| US-20170056376-A1 | SELECTIVE ACTIVATORS OF THE INTERMEDIATE CONDUCTANCE CA2+ACTIVATED K+ CHANNEL KCa3.1 AND THEIR METHODS OF USE | KCNN3, KCNN1, KCNN2 | ELANE 2595/4885NUDT1 2147/4885MAPT 4633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.